Source: International Congress 2018 – Clinical determinants and biomarkers of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Chua (Manila, Philippines), A. Albay (Manila, Philippines), M. Zamora (Manila, Philippines). Use of Inhaled corticosteroid (ICS)-containing regimen for COPD patients with high or low blood eosinophilia: A meta-analysis. 2020

Member's Comments

No comment yet.

Related content which might interest you: Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Low adherence to inhaled corticosteroids/long-acting ß2-agonists and biologic treatment in severe asthmatics Source: ERJ Open Res, 6 (2) 00017-2020; 10.1183/23120541.00017-2020 Year: 2020 Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study Source: International Congress 2018 – Eosinophils in airway disease Year: 2018 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019 Year: 2020 Blood eosinophils as a marker of response to inhaled corticosteroids in COPD Source: Eur Respir J 2016; 47:1374-1382 Year: 2016 Is sputum eosinophilia a good or poor predictor of benefit from inhaled corticosteroid therapy in asthma? Source: Eur Respir J 2002; 20: 1359-1361 Year: 2002 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Are inhaled corticosteroids increasing the “load” for some patients with COPD? Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017 Year: 2017 Use of inhaled corticoids and presence of eosinophilia in patients with COPD: TRACE Cohort Source: International Congress 2019 – Airway diseases and blood cells Year: 2019 Withdrawal of high-dose inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: a feasibility study in primary care. Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Pulmonary function test changes after cessation of inhaled corticosteroid therapy in asthma patients Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Inhaled antibiotic therapy in patients with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Blood eosinophil dose response to oral corticosteroids in a population of patients with severe asthma Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004